COVID-19 Disease Clinical Trial
Official title:
Retrospective Study of the Measurement of the Efficacy of MORPHINE in the Early Management of Dyspnea in COVID-19 Positive Patients With Moderate to Severe Impairment Without Objective of Resuscitation Management (Level of Care 3 and 4) at the Hospices Civils of Lyon
Morphine is used in the treatment of dyspnea and polypnea with a proven benefit on the
improvement of these symptoms, both etiologically and symptomatically. This medication is
used in particular in palliative care for this type of symptom.
The Sars CoV2 viral pneumonia table can lead to respiratory distress. In patients with
moderate to severe impairment without goal of resuscitation (level of care 3 and 4), the
introduction of morphine may sometimes be necessary to relieve respiratory symptoms. These
also lead to major exhaustion which can worsen the clinical picture. However, the
prescription of morphine is not systematic in front of a respiratory distress table.
The investigators hypothesized that early treatment with morphine lead to a better management
of dyspnea, quality of live and survival in COVID-19 positive participants patients when
there is not resuscitation objective management (level of care 3 and 4).
The objective is to measure the efficacy of morphine in the early management of dyspnea,
quality of life and survival in COVID-19 positive participants patients treated in the
Hospices Civils of Lyon during COVID-19 pandemic.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04984408 -
Efficacy, Immunogenicity and Safety of BBIBP-CorV Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.
|
Phase 3 | |
| Terminated |
NCT04642638 -
Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04587323 -
VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease
|
||
| Completed |
NCT04682873 -
A Clinical Study to Assess the Efficacy and Safety of Amizon® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus
|
Phase 3 | |
| Completed |
NCT04359212 -
Increased Risk of VTE and Higher Hypercoagulability in Patients Recovered in ICU and in Medical Ward for COVID-19
|
||
| Completed |
NCT05603130 -
Epidemiologic Register on Diabetes and COVID-19 in Tunisia
|
||
| Completed |
NCT04830800 -
A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC
|
Phase 1/Phase 2 | |
| Completed |
NCT04757792 -
Back to the Traditional: Anti-COX Drugs Can Improve the Outcome of COVID-19 Patients Admitted to ICU
|
||
| Active, not recruiting |
NCT04417257 -
Study of LAU-7b for the Treatment of COVID-19 Disease in Adults
|
Phase 2/Phase 3 | |
| Completed |
NCT04446377 -
A Study of LAM-002A for the Prevention of Progression of COVID-19
|
Phase 2 | |
| Active, not recruiting |
NCT04969172 -
A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Exosomes Overexpressing CD24 to Prevent Clinical Deterioration in Patients With Moderate or Severe COVID-19 Infection
|
Phase 2 | |
| Completed |
NCT04366024 -
A Novel Nomogram to Predict Severity of COVID-19
|
||
| Completed |
NCT04347369 -
A Retrospective Study of Neural Network Model to Dynamically Quantificate the Severity in COVID-19 Disease
|
||
| Completed |
NCT04787510 -
COVID-19 Disease and Coagulopathy: Assessment of Clotting Factor Levels in Patients With SARS-CoV-2 Infection
|
||
| Completed |
NCT05329220 -
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2
|
Phase 3 | |
| Active, not recruiting |
NCT05077267 -
ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects
|
Phase 2 | |
| Completed |
NCT04472013 -
Systematic Assessment of SARS-CoV-2 Neurotropic Capacity in Modestly and Critically Ill Patients, and Patients Who Died From COVID-19
|
||
| Active, not recruiting |
NCT04371354 -
Outcomes of Covid-19 Protective Measures in Endoscopy
|
||
| Not yet recruiting |
NCT04779359 -
Role of Lymphocyte Subsets and Laboratory Measurements in COVID-19 Disease
|